## **ATTACHMENT A**

## Clean Replacement/New Claims

Following herewith is a clean copy of each claim which replaces each previous claim having the same number and each new claim.

- 7. (Amended) Expression vector comprising an expression cassette in which a nucleotide sequence as defined in Claim 1 is placed under conditions allowing its expression in a host cell.
  - 9. Canceled.
- 10. (Amended) Monospecific antibody directed against a polypeptide according to Claim 5.
- 11. (Amended) Use of a nucleic acid according to Claim 1, or of a polypeptide specific for pathogenic *Neisseria* strains or of antigenic fragments thereof, for manufacturing a pharmaceutical composition intended for vaccination against *Neisseria*.
- 12. (New) A pharmaceutical composition comprising a nucleic acid according to Claim 1, in naked form or in combination with at least one agent facilitating transfection, and optionally in combination with a pharmaceutically acceptable vehicle.

- 13. (New) A pharmaceutical composition comprising a vaccination vector comprising a nucleotide sequence according to Claim 1, such as in particular a virus or a bacterium, and optionally in combination with a pharmaceutically acceptable vehicle.
- 14. (New) A pharmaceutical composition comprising a polypeptide according to Claim 5, optionally in combination with a pharmaceutically acceptable vehicle.